Aethlon To Be Uplisted To NASDAQ, CLLS Hits Milestone, LXK Gets FDA Nod

(RTTNews) - Aethlon Medical Inc.'s (AEMD.OB) common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015.

The company's lead therapeutic candidate is Aethlon Hemopurifier, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. According to the company website, the device is currently the subject of a human clinical study in India to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy. An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with the FDA.

AEMD.OB closed Wednesday's trading 8.48% higher at $7.16.

BG Medicine Inc. (BGMD) has implemented a one-for-four reverse stock split, and its common stock will open for trading on July 9, 2015 on a post-split basis.

The reverse stock split reduces the number of shares of the common stock outstanding from approximately 34.6 million pre-reverse split shares to approximately 8.6 million post-reverse split shares, said the company.

In the first quarter of 2015, the company reduced its net loss by 38% and cut its operating cash burn by 42% from the year-ago quarter.

BGMD closed Wednesday's trading at $0.43, down 11.44%.

Cellectis (CLLS) is all set to receive an undisclosed payment from Servier for achieving a significant milestone under a collaboration agreement with the French pharmaceutical company.

Cellectis and Servier entered into collaboration in February 2014 to develop and commercialize UCART19 to treat leukemia and 5 product candidates targeting solid tumors.

A phase I human clinical trial for UCART19 is planned for this year.

CLLS closed Wednesday's trading at $33.45, down 1.39%.

Lexmark (LXK) has received 510(k) Class II clearance from the FDA for Lexmark NilRead, a web-based, zero-footprint enterprise diagnostic viewer.

Lexmark NilRead is designed to help healthcare organizations in the U.S. perform diagnostic review and interpretation of a wide variety of medical imaging studies, including mammography and digital breast tomosynthesis (DBT) studies. The zero-footprint design of NilRead enables these large files to be delivered throughout a healthcare enterprise to local clinician workstations without download wait times. This is significant in a mammography screening environment where the daily volume of imaging studies reviewed is high, according to the company.

LXK closed Wednesday's trading at $43.65, down 2.50%.

Pieris Pharmaceuticals Inc. (PIRS) will be receiving its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed.

The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates.

Chau Khuong, a Partner at OrbiMed Advisors and Chairman of the Board of Directors of Pieris, stated, "To date, Pieris has received approximately $40 million in milestone and licensing payments as a result of its several collaborations. These payments speak to the ongoing success our Anticalin compounds are achieving in these partnerships".

PIRS closed Wednesday's trading at $2.50, down 5.66%.

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi's (SNY) phase III trial of investigational therapy Praluent met its primary endpoint, showing LDL-C reductions of more than 60% in Japanese patients.

The trial, dubbed ODYSSEY JAPAN, involved 216 Japanese patients with hypercholesterolemia at high cardiovascular (CV) risk and/or with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH).

In the U.S, Praluent is under FDA review, with a decision slated for July 24, 2015. Praluent was recommended for approval by an FDA panel on June 9, 2015. The FDA takes the Committee's advice into consideration, but is not bound by its recommendation.

In the European Union too, the Marketing Authorization Application for Praluent is currently under review by the European Medicines Agency.

REGN closed Wednesday's trading at $509.30, down 1.61%.